London - 13 December 2013 - The UK is hosting a G8 summit on dementia in London on 11 December. The
summit aims to develop co-ordinated global action on dementia.
see G8-dementia-summit
Janssen-Deloitte Investing in European Health R&D
Brussels, 7 October 2013: A report published today shows that European research and development (R&D) investments in health have stagnated since 2010, and this is the first time after decades of annual increases. The report was commissioned by Janssen Pharmaceutica NV and the research was conducted by Deloitte Health Economics group.
- The report-“Investing in European Health R&D"
- Presentation slides Jane Griffiths
- Investing in European health R&D – Press Release 7 October 2013
- Backgrounder on Janssen research initiatives and collaboration
- Report Executive Summary - Investing in European health R&D
- Graph: R&D Distribution and intensity by sector in the European Union
- Graph: Total health-related R&D in Europe in 2011
- Graph: Private (2011) and Public (2010) health-related R&D expenditures per country
- Graph: Evolution total health-related R&D 2004-2011 in EU and US
Source : Janssen health policy centre
Skolkovo Innovation Center: Russia investing $4 Billion in ‘innovation city’ Skolkovo to insemminate startup culture
9 August 2013
The Russian government is spending billions of dollars to manufacture startup culture.
Skolkovo is a science park outside of Moscow that aims to be the “Russian Silicon Valley.” It is the country’s largest state-sponsored innovation hub, and it will receive around $4 billion in state funding between now and 2020.
Skolkovo Foundation president Viktor Vekselberg said he expects to raise more than $11 billion in private investment by 2020 and that Skolkovo will not need government financing after 2025. He also predicted that this “innovation city” will contribute $6.5 billion to Russia’s economy over that time
The Russian government is spending billions of dollars to manufacture startup culture.
Skolkovo is a science park outside of Moscow that aims to be the “Russian Silicon Valley.” It is the country’s largest state-sponsored innovation hub, and it will receive around $4 billion in state funding between now and 2020.
Skolkovo Foundation president Viktor Vekselberg said he expects to raise more than $11 billion in private investment by 2020 and that Skolkovo will not need government financing after 2025. He also predicted that this “innovation city” will contribute $6.5 billion to Russia’s economy over that time
Bill & Melinda Gates Foundation: New partnership to fight poverty-related diseases
10 June 2013 -
The European Union and the Bill & Melinda Gates Foundation have today pledged to work together to fight HIV/AIDS, tuberculosis, malaria and other poverty-related diseases that together affect more than 1 billion people worldwide. The agreement, signed in Paris today by foundation co-chair Bill Gates and European Commissioner for Research, Innovation and Science, Máire Geoghegan-Quinn, creates a new strategic partnership for research in the area. Between 2007 and 2011, the foundation and the European Commission have contributed around 2.4 billion euro (3.1 billion USD) to research and development focused on poverty-related infectious diseases, supporting the development of more than 20 new and improved products.
The European Union and the Bill & Melinda Gates Foundation have today pledged to work together to fight HIV/AIDS, tuberculosis, malaria and other poverty-related diseases that together affect more than 1 billion people worldwide. The agreement, signed in Paris today by foundation co-chair Bill Gates and European Commissioner for Research, Innovation and Science, Máire Geoghegan-Quinn, creates a new strategic partnership for research in the area. Between 2007 and 2011, the foundation and the European Commission have contributed around 2.4 billion euro (3.1 billion USD) to research and development focused on poverty-related infectious diseases, supporting the development of more than 20 new and improved products.
The partnership will invest in research and development of life-saving interventions to improve the health and well-being of people living in developing countries. In addition to accelerating the development of much-needed drugs, vaccines and diagnostics, the two organisations will also seek to improve affordable and sustainable pathways to ensure that these products quickly reach those in greatest need.
More information:
Google Ventures is funding 8 healthcare and life sciences companies
April 2013 -
Google Ventures has been backing startups through its venture capital fund since 2009 and offers a pretty diverse range of services to entrepreneurs. It has eight healthcare and life science businesses among its portfolio companies spanning innovative areas such as DNA analysis, accelerated drug development, and oncology analytics.
Google Ventures has been backing startups through its venture capital fund since 2009 and offers a pretty diverse range of services to entrepreneurs. It has eight healthcare and life science businesses among its portfolio companies spanning innovative areas such as DNA analysis, accelerated drug development, and oncology analytics.
Actavis Watson Pharmaceuticals acquiert la société liégeoise Uteron Pharma pour 305 millions de dollars
January 2013
Actavis, New Jersey, (anciennement Watson Pharmaceuticals) a racheté Uteron
Pharma, société biopharmaceutique liégeoise, pour un montant de USD 150 million cash et USD 155 millions par versements d’étapes (potential future milestone payments).
Uteron Pharma, dont le personnel s’élève à 60 personnes, est une spin-off spécialisée dans la contraception et la fertilité, la ménopause et l’ostéoporose, les infections vaginales et les cancers féminins.
Uteron Pharma, dont le personnel s’élève à 60 personnes, est une spin-off spécialisée dans la contraception et la fertilité, la ménopause et l’ostéoporose, les infections vaginales et les cancers féminins.
Par ailleurs, cette
collaboration devrait permettre de poursuivre des projets de recherche
ainsi que le lancement sur le marché de produits demandant des
investissements importants, estime le CEO d’Uteron Pharma, Stijn Van
Rompay, qui souligne que le personnel ne sera pas affecté par ce rachat.
Source: RTL.be, Express.be, Actavis, Uteron
Uteron Pharma SA, Rue Saint Georges 5, B- 4000 Liège
Uteron Pharma SA, Rue Saint Georges 5, B- 4000 Liège
Subscribe to:
Posts (Atom)